| Dr Rizwana Khan, MD | |
|
2477 County Rd 516 Ste 103, Old Bridge, NJ 08857-4603 | |
| (732) 952-2222 | |
| (732) 952-8221 |
| Full Name | Dr Rizwana Khan |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 26 Years |
| Location | 2477 County Rd 516 Ste 103, Old Bridge, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154558419 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA08571500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Robert Wood Johnson Visiting Nurses, Inc | North brunswick, NJ | Home health agency |
| Robert Wood Johnson University Hospital | New brunswick, NJ | Hospital |
| Venetian Care & Rehabilitation Center, The | South amboy, NJ | Nursing home |
| Entity Name | New Jersey Medical And Health Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558673582 PECOS PAC ID: 9133300791 Enrollment ID: O20110302000334 |
News Archive
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostic professionals, submitted written comments on March 20 to the U.S. Food and Drug Administration (FDA) in response to the agency's request for feedback in association with its February 20, 2015 public workshop entitled, "Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests."
Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.
Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.
News outlets report on health care policy issues in California, D.C., Florida, Illinois, Kansas, Kentucky, Massachusetts, Minnesota and South Carolina.
A MUHC-led study identifies a gene responsible for Leber Congenital Amaurosis (LCA), the most common cause of congenital blindness in infants and small children.
› Verified 5 days ago
| Entity Name | Saint Peter's Healthcare System Physician Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548569361 PECOS PAC ID: 9537337258 Enrollment ID: O20110725000726 |
News Archive
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostic professionals, submitted written comments on March 20 to the U.S. Food and Drug Administration (FDA) in response to the agency's request for feedback in association with its February 20, 2015 public workshop entitled, "Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests."
Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.
Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.
News outlets report on health care policy issues in California, D.C., Florida, Illinois, Kansas, Kentucky, Massachusetts, Minnesota and South Carolina.
A MUHC-led study identifies a gene responsible for Leber Congenital Amaurosis (LCA), the most common cause of congenital blindness in infants and small children.
› Verified 5 days ago
| Entity Name | Aaa Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972028942 PECOS PAC ID: 0749548469 Enrollment ID: O20171229000007 |
News Archive
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostic professionals, submitted written comments on March 20 to the U.S. Food and Drug Administration (FDA) in response to the agency's request for feedback in association with its February 20, 2015 public workshop entitled, "Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests."
Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.
Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.
News outlets report on health care policy issues in California, D.C., Florida, Illinois, Kansas, Kentucky, Massachusetts, Minnesota and South Carolina.
A MUHC-led study identifies a gene responsible for Leber Congenital Amaurosis (LCA), the most common cause of congenital blindness in infants and small children.
› Verified 5 days ago
| Entity Name | Rwjbh Observation Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760095806 PECOS PAC ID: 5193137503 Enrollment ID: O20201209000008 |
News Archive
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostic professionals, submitted written comments on March 20 to the U.S. Food and Drug Administration (FDA) in response to the agency's request for feedback in association with its February 20, 2015 public workshop entitled, "Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests."
Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.
Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.
News outlets report on health care policy issues in California, D.C., Florida, Illinois, Kansas, Kentucky, Massachusetts, Minnesota and South Carolina.
A MUHC-led study identifies a gene responsible for Leber Congenital Amaurosis (LCA), the most common cause of congenital blindness in infants and small children.
› Verified 5 days ago
| Entity Name | Rwjbh Emergency Medicine Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912510041 PECOS PAC ID: 0941612840 Enrollment ID: O20201217002547 |
News Archive
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostic professionals, submitted written comments on March 20 to the U.S. Food and Drug Administration (FDA) in response to the agency's request for feedback in association with its February 20, 2015 public workshop entitled, "Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests."
Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.
Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.
News outlets report on health care policy issues in California, D.C., Florida, Illinois, Kansas, Kentucky, Massachusetts, Minnesota and South Carolina.
A MUHC-led study identifies a gene responsible for Leber Congenital Amaurosis (LCA), the most common cause of congenital blindness in infants and small children.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rizwana Khan, MD 2477 County Rd 516 Ste 103, Old Bridge, NJ 08857-4603 Ph: (732) 952-2222 | Dr Rizwana Khan, MD 2477 County Rd 516 Ste 103, Old Bridge, NJ 08857-4603 Ph: (732) 952-2222 |
News Archive
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostic professionals, submitted written comments on March 20 to the U.S. Food and Drug Administration (FDA) in response to the agency's request for feedback in association with its February 20, 2015 public workshop entitled, "Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests."
Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.
Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.
News outlets report on health care policy issues in California, D.C., Florida, Illinois, Kansas, Kentucky, Massachusetts, Minnesota and South Carolina.
A MUHC-led study identifies a gene responsible for Leber Congenital Amaurosis (LCA), the most common cause of congenital blindness in infants and small children.
› Verified 5 days ago
Mrs. Shahida M Abbas, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Cindy St, Old Bridge, NJ 08857 Phone: 732-607-2447 Fax: 732-607-2449 | |
Mr. Sanjeev Nayyar, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Perrine Rd, Suite 231, Old Bridge, NJ 08857 Phone: 732-525-0600 Fax: 732-525-9777 | |
Anam Rizvi, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 20 Shadybrook Ln, Old Bridge, NJ 08857 Phone: 973-932-9575 | |
Hashmi Rafeek, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Hospital Plz Ste 208, Old Bridge, NJ 08857 Phone: 732-360-2700 | |
Dr. Richard J Schaller, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2624 Hwy 516, Old Bridge, NJ 08857 Phone: 732-952-5000 Fax: 329-525-0057 | |
Dr. Maritza Georgette Parreno, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Perrine Rd, Suite 220, Old Bridge, NJ 08857 Phone: 732-721-1600 Fax: 732-721-1635 |